Alpha DaRT Trial Expansion Advances Pancreatic Cancer Study
FDA expands Alpha DaRT IMPACT trial to 40 patients, adding gemcitabine and nab-paclitaxel cohort in pancreatic cancer.
The FDA has approved an Investigational Device Exemption supplement to expand the ongoing IMPACT trial (NCT06698458) evaluating Alpha DaRT in pancreatic cancer, according to a news release. This update allows investigators to study Alpha DaRT in combination with an additional standard chemotherapy regimen gemcitabine plus nab-paclitaxel alongside the previously studied mFOLFIRINOX backbone.
The expansion increases the total planned enrollment from 30 to 40 patients and reflects a strategic effort to evaluate Alpha DaRT across both commonly used first-line chemotherapy approaches in pancreatic cancer. For oncology nursing professionals, this development highlights a growing interest in integrating novel intratumoral therapies with systemic regimens in a disease with persistently poor outcomes.
Trial expansion enables broader chemotherapy integration
The amended protocol introduces a cohort of 10 additional patients who will receive Alpha DaRT in combination with gemcitabine and nab-paclitaxel. Of these patients, five will have unresectable locally advanced disease and five will have metastatic pancreatic cancer.
This builds on the original study design, which enrolled 30 patients receiving Alpha DaRT with mFOLFIRINOX. With the expansion, the trial will now evaluate Alpha DaRT in combination with both leading first-line chemotherapy regimens, providing a broader assessment of feasibility and safety across treatment paradigms.
The decision to include both chemotherapy backbones may offer insight into how Alpha DaRT can be integrated into routine clinical workflows. From a nursing perspective, this introduces additional considerations for toxicity monitoring, coordination of multimodality care, and patient education regarding combined intratumoral and systemic treatment approaches.
Rationale for Alpha DaRT in pancreatic cancer
Pancreatic adenocarcinoma remains one of the most aggressive solid tumors, with limited therapeutic options for patients with unresectable locally advanced or metastatic disease.
Alpha DaRT is an investigational alpha-emitting radiation therapy designed for intratumoral delivery. The technology involves placement of radioactive sources directly into the tumor, allowing localized radiation with the goal of inducing tumor cell death while minimizing exposure to surrounding tissues.
The rationale for combining Alpha DaRT with systemic chemotherapy lies in the potential for synergistic activity. Chemotherapy addresses systemic disease burden, whereas Alpha DaRT provides targeted local tumor control. This combined modality approach may be particularly relevant in pancreatic cancer, where local tumor progression contributes significantly to morbidity.
Study design and treatment approach
The IMPACT trial is a multicenter pilot study evaluating the safety, feasibility, and preliminary efficacy of Alpha DaRT in combination with chemotherapy in patients with newly diagnosed pancreatic adenocarcinoma.
Patients enrolled in the study receive standard-of-care chemotherapy—either mFOLFIRINOX or gemcitabine plus nab-paclitaxel—alongside Alpha DaRT. The device is implanted directly into the primary tumor using ultrasound-guided endoscopic techniques, allowing for precise intratumoral delivery.
The primary objectives include assessment of safety and feasibility, particularly focusing on the ability to successfully implant the Alpha DaRT sources and monitor for device-related adverse events. Secondary endpoints include early signals of clinical activity.
Follow-up is conducted for up to six months after enrollment, enabling evaluation of both short-term safety and preliminary treatment response.
The IMPACT trial targets patients with newly diagnosed, histologically confirmed pancreatic adenocarcinoma that is considered unresectable. This includes both locally advanced and metastatic disease.
The expanded study aims to enroll up to 40 patients in total, with an approximately equal distribution between locally advanced and metastatic populations.
Eligible patients may be chemotherapy-naïve or within the first four cycles of initial systemic therapy, ensuring that Alpha DaRT is introduced early in the treatment course.
For oncology nurses, this population presents complex care needs, including symptom burden from advanced disease, coordination of procedural interventions, and management of combination therapy toxicities.
Clinical and nursing implications of trial expansion
The expansion of the IMPACT trial represents a meaningful step in evaluating Alpha DaRT within contemporary pancreatic cancer treatment frameworks. By incorporating both mFOLFIRINOX and gemcitabine plus nab-paclitaxel, the study aligns with real-world clinical practice and may enhance the generalizability of findings.
Key considerations for oncology nursing professionals include:
- Monitoring for overlapping toxicities associated with chemotherapy and localized radiation delivery
- Supporting patients undergoing endoscopic implantation procedures
- Educating patients on the role of investigational intratumoral therapies
- Coordinating multidisciplinary care across oncology, gastroenterology, and interventional teams
Additionally, the trial’s expansion may extend enrollment timelines into the third quarter of 2026, reflecting the logistical complexity of integrating new cohorts and obtaining site approvals.
Reference
- Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel). News release. Alpha Tau Medical Ltd. April 24, 2026. Accessed April 24, 2026. https://www.globenewswire.com/news-release/2026/04/23/3280027/0/en/alpha-tau-announces-fda-approval-of-ide-supplement-to-expand-alpha-dart-impact-trial-to-patients-with-pancreatic-cancer-receiving-gemcitabine-with-abraxane-nab-paclitaxel.html.
